You will probably have to type in the link but it is well worth the effort. It is in regards to
Signaling Pathways regarding certain cancers and aptosis.
This is just a sample of the blood tests measuring BP-3 levels in the blood. The thing to take note of is how important it is to keep things running smoothly and balanced. We will start hearing more about it as we approach 2017 and the end of patent issues.
PS- Somebody is brewing this stuff up somewhere. Iplex keeps popping up in stamina trials etc....
Insulin-like Growth Factor-binding Protein 3 (IGFBP-3) Blood Test
Measure this protein which is the major carrier of IGFs in plasma.
Preparation No fasting required
Test Type Blood
Test Results 3-4 days
Also Known As: IGFBP-3
Approximately 95% of the IGF-I and IGF-II are bound to IGFBP-3, which makes this protein the major carrier of IGFs in plasma. One of the principal functions of binding proteins is to extend the half-life of the IGFs from eight minutes to several hours. In this way, IGFBP-3 acts as a stabilizer, providing a constant level of IGF. The serum level of IGFBP-3 appears to be a constant over 24 hours and the protein was found to be growth hormone (GH) dependent, which makes the detection of IGFBP-3 very useful in the evaluation of growth hormone secretion. Single IGFBP-3 measurements correlate significantly with the logarithm of the integrated spontaneous GH secretions.
Advantages of IGFBP-3 over IGF-1 are the higher levels in young children which gives a better discrimination between normal and subnormal levels. The IGFBP-3 assay is also used to diagnose children with short stature having normal GH levels. Some children with short stature give subnormal IGF-I levels despite normal GH levels. IGFBP-3 was found to be a more reliable parameter for monitoring the efficacy of therapy; therefore, it is a useful adjunct to the measurement of IGF-I.
Sentiment: Strong Buy
Does anyone know what antibiotic or the delivery method they use to treat this. It seems to be pretty nasty and tough to treat and keeps popping up. It would seem it would fall under the NTM catagory somewhere. Maybe it is a totally different bug to deal with. I was just wondering if it would be on Insmed's radar.
181,000 cases multiplied by $61,000 per patient per year divided by 64,000,000 shares with a multiple of say 10 for the rest of the world and the per share price makes 250 look conservative. Keep your fingers crossed.
This MB is pretty entertaining with all the political b.s. that has been going on here now for years. But ETFC is getting their house in order and getting ready to make a run to some new levels. How about we switch gears and talk about ETFC once in awhile, considering this is a ETFC MB, and see if can make some money. This thing is getting ready to rock and roll upwards and who cares about Hillary or Rick Perry on this MB. The only thing the politicians are gonna do is take your money, so you better make as much as you can and this stock is a good place to be to offset their nonsense.
If all the gang shows back up with all the nonsence then we will know iplex is back on the table. Just IGFBP3 alone is worth some bucks.
So let's see....I think Merck is still sitting on the manufacturing lab. "Follow on" biologics hasn't panned out quite the way they had hoped, and people are still getting their hands on Iplex for various reasons because that is what they want.
Maybe even cocktail Iplex with various chemo drugs like they do now with Decadron and Benadryl and keep your body running smoothly while they go after the illness. Just a thought...
Like I said, it should get interesting and this time we also have Arikayce in the loop which is a pretty spectacular item all on its own.